WorkflowIT & Data

The complete guide · November 2026

Computerized system periodic review, explained.

A laboratory or plant system is tested and signed off as fit for use before it goes live, a step called validation. Then people join and leave, patches arrive, and instruments get added. A periodic review is the scheduled look back that asks whether that proof still holds, using the system's own records for the year.

This guide is for anyone who owns, reviews or signs for a validated system in drug, biotech or device work: IT Quality and computer system validation (CSV) leads, system owners, data integrity leads, quality assurance (QA) reviewers and site quality heads. It also serves leaders deciding whether to automate the work. No background needed.

See one case, screen by screen →
Watch with transcript →
A quick example · fictional

Imagine you are the IT Quality lead at a drug manufacturer, Cobbleford Pharma. It is October 7, 2026. The periodic review of ChromaVault CDS, the system that holds release and stability test results for the Plant 3 laboratory, is due October 15. Your first stop is the identity governance tool, which tracks who can log in to what. All four quarterly access reviews, where managers confirm that each account is still right, show as completed. It looks clean.

Then you open a second tool, the deviation records, where things that went off plan are logged, and put two dates side by side. Two analysts left the company on June 20. The access review that should have caught them was due July 8.

Access review, Q2
Due
Jul 8
Completed
Jul 31, 23 days late
HR and the accounts
Analysts left
Jun 20
Accounts removed
Jul 31, 41 days later
No logins after they left, and still a findingRaise it, name an owner, add an interim checkbecause 16 weeks passed without an access review, and only the two records together show it.

A good review catches what no single tool shows: the gap between what your procedures expect and what a system's year holds.

Computerized system periodic review guide
Part A · Understand it

Keeping a GxP system in its validated state: what periodic review is, what the rules ask and where it fails

What the review decides, which rule says what as of November 2026, what the 2025 draft of Annex 11 would add, how frequency is worked out, what FDA cites and how teams run it today, explained without selling anything. If you are new to computer system validation, start here. GxP, in the heading above, is shorthand for the good practice rules: manufacturing (GMP), laboratory (GLP), clinical (GCP) and others.

01 · In plain words

A periodic review asks whether a validated system is still the system you validated

Drug companies run on software. A chromatography data system, or CDS, stores the test results that decide whether a batch can be released. A laboratory information management system, or LIMS, tracks every sample. A manufacturing execution system runs the electronic batch record. A clinical team enters trial data into an electronic data capture system. Regulators call all of these computerized systems, and when they touch regulated work the company must first prove, with planned tests and signed records, that each one does its job. That proof is called validation.

Validation describes one moment. The next morning the system starts to drift away from that moment. An analyst leaves and her account stays open. A driver is patched in a hurry to stop instruments dropping off mid-run. Six more instruments get connected. The operating system underneath reaches the end of its support. Each change may be small and may have been handled properly. Nobody has looked at them together.

A periodic review is the scheduled moment when someone does. They gather what happened to the system over a period, usually a year for an important one: its changes, incidents, deviations, access reviews, backups, audit-trail reviews and the actions left over from last time. They compare it with what the company's own procedures said should have happened. Then they write a conclusion: this system remains in its validated state, or it does with some actions, or it needs a closer look before anyone relies on it further.

Most of the effort goes to collecting, because the evidence sits in half a dozen tools that were never designed to talk to each other. Each tool looks fine alone. The trouble usually sits between them, in a late access review that overlaps with two people leaving, or an emergency change closed with a note saying the proof would follow. An inspector who reads the year in order will see that. The review exists so that you see it first.

One system's year, from go-live to the next review's date

  1. The system is validatedTests pass, a validation summary is signed and the system goes live with a risk tier that sets how often it will be reviewed.
  2. A year of ordinary changePatches, incidents, new users, departures, backups and monthly audit-trail reviews pile up in separate tools.
  3. The evidence is gatheredSomeone exports the period's records from each tool and pulls last year's review and its open actions.
  4. The year is read against the proceduresEach record is compared with what the procedures expected, gaps are found, findings are written and a conclusion is proposed. This is the step this guide is about.
  5. People decide and signA reviewer decides each finding, a system owner or quality head approves, actions go to the quality system and the next date is set.

Step 4 is the subject of this guide. The people, company and figures in the example are fictional.

Green tools, no fixed interval and three more surprises about periodic review

Every tool can be green while the system has a gap

In the example at the top of this page, the access tool shows four completed reviews and the deviation tool shows one closed record. The 16-week hole only appears when both are laid out on one calendar.

No rule says "every 12 months"

Annex 11, the EU's rule on computerized systems in drug manufacturing, sets no interval.1 The European Medicines Agency (EMA) ties it to criticality in a Q&A, and PIC/S, a co-operation scheme of drug inspection authorities, and the draft revision of Annex 11 ask for a frequency you can justify by risk.2,3,4 The only review interval we found in the texts we read is OECD's: a user review "at least yearly", for good laboratory practice systems.5 We did not read the paid text of GAMP 5, an industry guide. The 12, 24 and 36 months you see in many procedures are company choices.

FDA's drug rule never uses the words

21 CFR 211.68 asks for computers to be "routinely calibrated, inspected, or checked according to a written program", with access, input and backup controls.6 The words "periodic review" do not appear in it. What FDA cites under it is what a good review would have caught, as section 9 shows.

A review can sometimes be skipped, in writing

OECD lets a test facility exclude low-criticality systems when the exclusion is justified by risk, and postpone a review after a major revalidation.5 So a blanket "every system, every year" can be more work than the rules ask for, and a thin one can still miss what they expect.

Validated state, access review, audit-trail review, CAPA: the words this work runs on

Validated state

The condition in which a system still does what its validation proved, under controls that are still working. A review confirms it or says it no longer holds.

Access review

A manager confirming that each person's account and role on a system are still right. Also called a user access review or an access certification.

Audit-trail review

A check of the system's own log of who changed what. A periodic review looks at whether those checks happened and were followed up.

CAPA

Corrective and preventive action: a tracked fix for a problem, with an owner, a due date and a check that it worked.

Fourteen terms are defined in the one-page summary.

02 · What the review decides

One review, three possible conclusions, and five other checks that get confused with it

In shortA computerized system periodic review ends in a decision about one system over one period: the system stays validated, stays validated with actions, or needs re-assessment. It sits in the operating years of a system's life, and it reads the results of smaller routine checks without replacing them.

The periodic review sits in the operating years and feeds the next round of change

A typical life cycle for a validated system. The final review at retirement appears in the 2025 draft of Annex 11.

  1. 1Validate

    Plan, test and sign before first use.

    CSV lead, system ownerBefore go-live
  2. 2Operate

    Changes, incidents, access and backups, each with its own routine.

    IT, users, QAEvery day
  3. 3Review

    Read the period, find gaps, conclude.

    IT Quality, system ownerBy risk tier
  4. 4Act

    Findings become CAPAs. Some changes need partial revalidation.

    Named ownersDated
  5. 5Retire

    Keep records readable. A final review closes the file.

    System owner, QAEnd of use

Our reading of the sources 4,7

Show the numbers
StepWhat happensWhoTime
ValidatePlan, test and sign before first use.CSV lead, system ownerBefore go-live
OperateChanges, incidents, access and backups, each with its own routine.IT, users, QAEvery day
ReviewRead the period, find gaps, conclude.IT Quality, system ownerBy risk tier
ActFindings become CAPAs. Some changes need partial revalidation.Named ownersDated
RetireKeep records readable. A final review closes the file.System owner, QAEnd of use
ConclusionWhat it saysWhat usually follows
Remains validatedEvery expectation was met or explained. No action is needed.Keep the frequency. Set the next date.
Validated, with actionsThe system is fit for use. Gaps exist, none of which puts reported results in doubt, and each has an owner and a date.CAPAs raised. Interim checks where a fix takes time. Frequency kept or shortened.
Re-assessment neededContinued use needs a risk assessment or revalidation first. The draft of Annex 11 frames this as whether "re-validation (complete or in parts) is required".4Quality head involved. Possible hold on use. Impact on past results assessed.

How a system periodic review differs from revalidation, an annual product review and an audit

CheckIts questionHow oftenHow it relates
System periodic reviewIs this system still in its validated state, given the period's records?Risk-basedThe subject of this guide
RevalidationDo tests still prove that it works, after a change or a finding?When triggeredA review can trigger one, in whole or in part
Annual product reviewDo this drug's batches show a need to change its specifications or procedures? 21 CFR 211.180(e) requires it "at least annually".8At least yearlyAbout a product, and easy to confuse because of the word "review"
Audit-trail reviewDo the log entries for this data or period show anything wrong?Set by procedure, often per batch or monthAn input: the periodic review reads whether it was done
Access reviewShould these people still have these roles?Set by procedure, often quarterlyAn input, and a common source of findings
Internal audit or self-inspectionIs the quality system working across an area?Audit planBroader, and independent. It may sample periodic reviews

You will also see this work called CSV periodic review, periodic review of computerised systems, GxP system periodic review, validated state review or Annex 11 periodic evaluation. They mean the same job.

03 · The rules and their dates

Annex 11 clause 11, PIC/S, OECD No. 17, ICH E6(R3) and 21 CFR 211.68: who asks for a review, in what words

In shortEU GMP has asked for periodic evaluation since 2011, and that text is still the one in force as of November 3, 2026. PIC/S, OECD and EMA's clinical guideline ask for much the same. ICH, the International Council for Harmonisation, says a review "may be appropriate". FDA's drug rule asks for a written program of checks and for access and backup controls, and leaves the rest to you. GAMP 5 is industry guidance, and many companies build their procedures on it.

Fifteen years of periodic review text, and the 2011 clause is still the EU's rule

Status as read on November 3, 2026.

  1. Jun 2011Annex 11 applies

    Clause 11, periodic evaluation.

  2. 2016OECD GLP No. 17

    Section 3.6, with a yearly user review.

  3. Jul 2021PIC/S PI 041-1

    Cumulative effect of changes, risk-based frequency.

  4. Jul 2022GAMP 5, second edition

    Industry guidance.

  5. Mar 2023EMA clinical systems guideline

    Section A2.9.

  6. Jan 2025ICH E6(R3), Step 4

    Review "may be appropriate".

  7. Jul 2025Annex 11 draft

    Consultation to October 7, 2025. Section 14 on periodic reviews.

Source 1,5,3,7,9,10,11,4,12

Show the numbers
WhenWhat
Jun 2011Annex 11 applies
2016OECD GLP No. 17
Jul 2021PIC/S PI 041-1
Jul 2022GAMP 5, second edition
Mar 2023EMA clinical systems guideline
Jan 2025ICH E6(R3), Step 4
Jul 2025Annex 11 draft
Q4 2026Target for final text
Area and textWhat it saysStatus, November 2026
GMP, EU: Annex 11, clause 11Systems "should be periodically evaluated to confirm that they remain in a valid state and are compliant with GMP". Include, "where appropriate", functionality, deviations, incidents, problems, upgrade history, performance, reliability, security and validation status reports.1In operation since June 30, 2011. EudraLex lists it at "revision January 2011".13 A revision is in draft (section 4).
GMP, EU: EMA Q&A on Annex 11, question 7"The time period for revaluation and revalidation should be based on the criticality of the system."2February 2011
GMP and good distribution practice (GDP): PIC/S PI 041-1, section 9.3Evaluate periodically "to ensure continued compliance with respect to data integrity controls", including "any cumulative effect of changes". Inspectors "verify that systems have been subject to periodic review".3In force since July 1, 2021
GMP, US: 21 CFR 211.68A "written program designed to assure proper performance" of computers. Controls so that record changes are made "only by authorized personnel". Input and output checked. A backup file maintained.6In force. The 2025 CFR edition is the newest on govinfo.
Electronic records, US: 21 CFR Part 11Validation, audit trails, and "limiting system access to authorized individuals" in 11.10.14 Password issuances "periodically checked, recalled, or revised" in 11.300.15In force
GLP: OECD No. 17, section 3.6Review to confirm systems "remain in a validated state, are compliant with GLP and continue to meet stated performance criteria". Depth set by complexity and GLP criticality. "A periodic user review should be done ... at least yearly."5Published 2016
GCP: ICH E6(R3), section 4.3.4(d)"Periodic review may be appropriate to ensure that computerised systems remain in a validated state throughout the life cycle of the system."11Final version adopted at Step 4, January 6, 2025. Annex 1 in effect in the EU from July 23, 2025.
GCP, EU: EMA guideline, section A2.9Assess "whether the system can still be considered to be in a validated state". The list runs from infrastructure changes to "new regulation", "review of system accesses" and agreements with service providers.9Final version adopted March 7, 2023
GCP, US: FDA Q&A on electronic systems, question 12"Periodic review of the audit trail may be helpful." It speaks of audit trails and does not ask for a review of the whole system.10Final, October 2024
Medical devices, US: QMSR and FDA's CSA guidanceThe Quality Management System Regulation incorporates ISO 13485:2016.16 FDA's Computer Software Assurance guidance covers software used in device production and the quality management system, so it does not set periodic review for drug systems.17QMSR in effect February 2, 2026. CSA final issued February 3, 2026.
Industry guidance: ISPE GAMP 5, second editionA risk-based approach to GxP computerized systems. ISPE's published table of contents lists Appendix O8, Periodic Review, and its public course page stresses "documented procedures, periodic reviews, and clear roles".7,18 We did not read the paid text, so we cannot say what O8 asks about frequency.July 2022. Industry guidance, which carries no legal force.
Reading these side by side. The EU texts say "should", and inspectors read a company against them and against its own procedures. FDA's rule says "shall", about a narrower set of controls. A global company usually writes one periodic review procedure to the widest of these texts and runs it for every market. That is a company choice, and it spares running a separate procedure per market.
04 · The Annex 11 draft

Annex 11 revision status: what the 2025 draft would change about periodic reviews

In shortAs of November 3, 2026, the draft has not replaced the 2011 text. If it is adopted as written, a 44-word clause becomes a section of about 300 words with a named scope, a justified frequency and a final review at retirement. A company can add most of what it lists to a review template now.

Status, dated. The Commission's EudraLex Volume 4 page, read November 3, 2026, lists Annex 11 at "revision January 2011" and no Annex 22.13 The joint European Commission and PIC/S consultation ran from July 7 to October 7, 2025.4 EMA's inspectors' work plan for 2026 to 2028 sets Q4 2026 as the target for giving the Commission a final text.12 That is a target for a hand-over, with no adoption or effective date published. Any article saying the new Annex 11 "applies" is ahead of the record.
The periodic review text grows about sevenfold in the draft

Words in the periodic review clause, by our count of each published text.

Annex 11 (2011), clause 1144 words
Draft Annex 11 (2025), section 14313 words

Source 1,4

Show the numbers
TextWords
Annex 11 (2011), clause 1144 words
Draft Annex 11 (2025), section 14313 words
TopicAnnex 11, 2011 (in force)Draft, 2025 (not in force)
The questionRemain "in a valid state" and "compliant with GMP"1Remains "fit for intended use" and in "a validated state", "or whether changes should be made and re-validation (complete or in parts) is required"4
FrequencyNot stated in the clause"Established and justified based on the risk the system poses to product quality, patient safety and data integrity"4
Changes"Upgrade history"Hardware, software, configuration, platform, infrastructure, interfaces and documentation. "The combined effect of multiple changes in this, and in other systems". Undocumented changes found "by means of configuration auditing"4
Past actionsNot named"Actions from previous periodic reviews, audits and inspections, and corrective and preventive actions"4
Access and audit trailsElsewhere: audit trails "regularly reviewed" in clause 9, access changes recorded in clause 12.31"Conduct of, and actions from, audit trail reviews, access reviews, and risks assessments" sit inside the review. Section 11.11 adds recurrent access reviews where managers confirm access4
Shared accountsNot namedSection 11.1: shared accounts, except read-only ones, "constitute a violation of data integrity"4
BackupRestore ability "monitored periodically", clause 7.21"Adequacy of backup procedures, restore tests and disaster recovery plans." Section 16.6 asks for documented restore tests4
SuppliersHandled elsewhere"Contracts and key performance indicators (KPI) with vendors and service providers"4
Rule changesNot named"Changes to regulatory requirements"4
RetirementNot named"A final review should be conducted when the system is taken out of use"4

Treat the draft as a sign of where the rule is heading. Its list can be added to a review template today, because nothing in the 2011 text stops you reading more. Wait for the final text before you rewrite your procedure's mandatory wording, since comments may have changed the draft's words.

05 · What each text covers

Twelve topics across six texts: what a periodic review template should cover

In shortLine the texts up and a common core appears: changes, incidents, deviations and security. Access, audit trails and backup are asked for everywhere, often in a separate clause. Past actions, the combined effect of changes and new regulation are the newer asks, and a template built only on the 2011 clause can miss them.

Only the 2025 draft names last review's actions as part of the review

How each text treats each topic. The last column is FDA's list of what it asks a firm to assess after a data integrity finding, shown because it reads like a review scope; it does not define a periodic review.

Not namedOther clauseReview clause
Annex 11, 2011Draft Annex 11PIC/S PI 041-1OECD No. 17EMA A2.9FDA letter listChanges and upgradesReview clauseReview clauseReview clauseReview clauseReview clauseReview clauseCombined effect of changesNot namedReview clauseReview clauseNot namedReview clauseNot namedIncidents and problemsReview clauseReview clauseNot namedReview clauseReview clauseNot namedDeviations and CAPAsReview clauseReview clauseReview clauseReview clauseReview clauseReview clausePrevious review's actionsNot namedReview clauseNot namedNot namedNot namedNot namedAccess reviewsOther clauseReview clauseOther clauseReview clauseReview clauseReview clauseAudit-trail reviewsOther clauseReview clauseOther clauseOther clauseOther clauseReview clauseBackup and restoreOther clauseReview clauseOther clauseOther clauseReview clauseReview clauseSecurityReview clauseReview clauseOther clauseReview clauseReview clauseReview clauseSuppliers and contractsOther clauseReview clauseOther clauseOther clauseReview clauseNot namedDocuments and proceduresOther clauseReview clauseOther clauseOther clauseOther clauseNot namedNew regulationNot namedReview clauseNot namedNot namedReview clauseNot named

Our reading of the sources 1,4,3,5,9,19

Show the numbers
Annex 11, 2011Draft Annex 11PIC/S PI 041-1OECD No. 17EMA A2.9FDA letter list
Changes and upgradesReview clauseReview clauseReview clauseReview clauseReview clauseReview clause
Combined effect of changesNot namedReview clauseReview clauseNot namedReview clauseNot named
Incidents and problemsReview clauseReview clauseNot namedReview clauseReview clauseNot named
Deviations and CAPAsReview clauseReview clauseReview clauseReview clauseReview clauseReview clause
Previous review's actionsNot namedReview clauseNot namedNot namedNot namedNot named
Access reviewsOther clauseReview clauseOther clauseReview clauseReview clauseReview clause
Audit-trail reviewsOther clauseReview clauseOther clauseOther clauseOther clauseReview clause
Backup and restoreOther clauseReview clauseOther clauseOther clauseReview clauseReview clause
SecurityReview clauseReview clauseOther clauseReview clauseReview clauseReview clause
Suppliers and contractsOther clauseReview clauseOther clauseOther clauseReview clauseNot named
Documents and proceduresOther clauseReview clauseOther clauseOther clauseOther clauseNot named
New regulationNot namedReview clauseNot namedNot namedReview clauseNot named

FDA's standard request in recent warning letters asks a firm with data integrity problems to assess each system's "configurations, administrative rights, password controls, audit trails capabilities and state of implementation", its "qualification/validation status, deviation history, backup capabilities, network requirements, completeness of data records, suitability of current hardware/software for its intended use(s), change management, and management oversight".19 It is the same list a thorough reviewer reads, written after the fact and under pressure. A company can answer those questions in its own time, every year.

The grid is our reading of each published text. A cell marked "Not named" means the text does not name the topic, and a company's own procedure may still rightly cover it.

06 · The six places a year lives

Six tools, six owners: where the evidence for one system's periodic review sits

In shortOne system's year usually sits in six places, owned by six groups. Each export answers a small question well. The review's real questions need two of them at once, which is why a reviewer who reads tool by tool can pass everything and miss the finding.

Where it sitsWhat you pullWhat you checkUsually owned by
IT service management (the service desk)Changes, incidents, problems, configuration itemsEach GxP change has an impact assessment, approval, test and verification. Emergency changes were verified within your limit. Incidents link to a problem and a fix.IT operations
Quality systemDeviations and CAPAs naming the system, and actions from the last reviewOn time, effective, and whether any record affected reported results.QA
Identity governance (who can log in to what)Access certifications, account lists, privileged (administrator) accountsReviews on time. Departures removed within your limit. No shared accounts that can change data.Identity and access team
Backup reportsDaily job reports, restore testsJobs succeeded or were re-run. Restores were tested as planned and the data was readable.Infrastructure team
Audit-trail review registerThe register and signed review formsEvery required review done on time, and anything it found followed up.Data integrity lead, laboratory
Validation archiveLast review, validation summaries, standard operating procedures (SOPs), supplier assessmentDocuments reflect the system as it now runs. Supplier assessment is current. Training on changed procedures is complete.CSV team
Each gap in the example takes at least two sources to see

Which sources hold part of each gap in this guide's fictional case.

SilentHolds part of it
IT service managementQuality systemIdentity toolBackup reportsAudit-trail registerArchiveLate access review, departed usersSilentHolds part of itHolds part of itSilentSilentHolds part of itEmergency change never verifiedHolds part of itSilentSilentSilentSilentHolds part of itShared administrator accountSilentHolds part of itHolds part of itSilentSilentHolds part of itMissed audit-trail reviewSilentSilentSilentSilentHolds part of itHolds part of it

Fictional example from this guide

Show the numbers
IT service managementQuality systemIdentity toolBackup reportsAudit-trail registerArchive
Late access review, departed usersSilentHolds part of itHolds part of itSilentSilentHolds part of it
Emergency change never verifiedHolds part of itSilentSilentSilentSilentHolds part of it
Shared administrator accountSilentHolds part of itHolds part of itSilentSilentHolds part of it
Missed audit-trail reviewSilentSilentSilentSilentHolds part of itHolds part of it

Spreadsheets and paper make this harder. A hybrid system prints results that a reviewer has to link back to electronic records by hand, and R.D. McDowall, in a 2011 practitioner article series in the journal Spectroscopy, calls that correlation "the biggest challenge" in a review of a hybrid system.20 Exports also go stale: a reviewer who pulls access data on Monday and writes on Friday should say which day the data was true.

07 · Working out frequency

Risk-based periodic review frequency, worked through on a 64-system inventory

In shortRules ask you to justify the interval by risk, and companies turn that into tiers. One consultancy's published advice is annual for high-impact systems and two to three years for lower-risk ones. That is a convention, and no rule sets it. The arithmetic is simple, and it tells you how many reviews you are signing up for.

A consultancy's 2025 article says high-impact systems such as electronic batch records, manufacturing control and LIMS are reviewed "typically annually", and lower-risk systems such as training platforms and document repositories "every two to three years".21 Take the fictional inventory in this guide's example: 64 GxP systems, split into 22 high, 26 medium and 16 low.

Reviews a year = high ÷ 1 + medium ÷ 2 + low ÷ 3

22 ÷ 1 + 26 ÷ 2 + 16 ÷ 3 = 22 + 13 + 5.3 = about 40 reviews a year. At this guide's estimate of about 25 hours a review, that is about 1,000 hours a year, mostly collecting, for one company. Sample figures.

64 systems on a 12, 24 and 36 month cycle make about 40 reviews a year

Fictional inventory. Cycle lengths are the sample company's setting, which it must justify by risk.

Systems on the inventoryReviews in a year
High risk, every 12 months2222
Medium risk, every 24 months2613
Low risk, every 36 months165

Fictional example from this guide

Show the numbers
TierSystems on the inventoryReviews in a year
High risk, every 12 months2222
Medium risk, every 24 months2613
Low risk, every 36 months165

What pushes a chromatography data system up a tier and a read-only archive down

Direct GxP impact and frequent change earn the shortest cycle

Illustrative positions. Your own risk assessment decides.

Direct GxP impact →
Short cycle
Shortest cycle
Long cycle
Medium cycle
ChromatographyBatch recordLIMSTrial data captureTraining systemRead-only archiveLocked spreadsheet
How often the system changes →

Illustrative · replace with your own numbers

Show the numbers
ItemHow often the system changes (0–1)Direct GxP impact (0–1)
Chromatography0.860.72
Batch record0.180.82
LIMS0.860.58
Trial data capture0.180.62
Training system0.840.22
Read-only archive0.120.26
Locked spreadsheet0.220.10
FactorMoves the reviewWhere the idea comes from
GxP criticalityMore direct impact means a shorter cycleEMA Q&A: "based on the criticality of the system"2
Cumulative changeMany changes since the last review can mean an earlier onePIC/S: "considering the cumulative effect of changes"3
ComplexityCustom or heavily configured means deeper. Simple standard software can mean lighter, or excluded with a written reasonOECD paragraphs 89 and 905
Recent revalidationA major revalidation can justify postponingOECD paragraph 905
Last review's findingsAn uncovered high finding can shorten the next cycleCommon practice; your procedure decides
Access to dataA separate, shorter clock for user reviewsOECD: "at least yearly"5. Draft Annex 11 11.11: "commensurate with the risks"4
08 · The date arithmetic

The sums behind a finding: days late, days exposed and what 99.5% backup success hides

In shortMost periodic review findings come down to subtraction: a due date from a completion date, a departure from an account removal. Done by hand across six tools it is slow and easy to skip. Here are the ones that matter, worked on the fictional year in this guide's example.

The checkThe sum, on the fictional caseThe reading
Days late on an access reviewCompleted Jul 31 minus due Jul 8 = 23 daysOver the sample site's 14-day tolerance. Three of four were on time.
Longest gap between access reviewsApr 9 to Jul 31 = 113 days, about 16 weeks, on a quarterly cycleA "quarterly" review can hide a third of a year without one.
Days a departed user stayed activeLeft Jun 20, removed Jul 31 = 41 days. The sample limit is 5 working days.The account log showed no logins after they left, which limits the impact. The exposure is still a finding.
Change verification36 of 37 changes verified after go-liveThe one missed is an emergency hotfix on 46 instruments. Weight matters more than the percentage.
Backup success363 of 365 = 99.5%, with two failures re-run the same dayThe job rate looks fine and tells you nothing about whether a restore works. Check the restore tests apart.
Audit-trail coverage11 of 12 monthly reviews on time. August caught up on Sep 12.Also read the procedure: it has no rule for a plant shutdown.
Age of last year's open actionDue Mar 31, still open Oct 7 = 190 days overdueThe same risk carried for another review cycle.
A quarterly access review ran 113 days between checks in the example

Days between completed access reviews for the fictional system.

Oct 6 to Jan 793 days
Jan 7 to Apr 992 days
Apr 9 to Jul 31113 days

Fictional example from this guide

Show the numbers
IntervalDays
Oct 6 to Jan 793 days
Jan 7 to Apr 992 days
Apr 9 to Jul 31113 days
Why subtraction is not enough. The sums find the candidates. Deciding what they mean takes a person who knows the system: whether a departed user could still reach the data, whether a shutdown makes a missed review harmless, whether an unverified hotfix touched how results are calculated. That judgment is the part of the review worth an expert's hour.
09 · What FDA cites

21 CFR 211.68(b) in FDA's data and warning letters: shared logins, administrator rights and missing backups

In shortFDA cited the computer control line of 21 CFR 211.68(b) 87 times in fiscal 2025 on drug Form 483s, the lists of observations given at the close of an inspection. That was the sixth most cited of 316 lines, by our tally. Recent warning letters describe the same small set of failures, and each is something a periodic review should have raised before an investigator did.

Computer control citations rose to about 12 per 100 drug Form 483s

21 CFR 211.68(b), access to records (FDA cite 1263), per 100 drug Form 483s issued from FDA's system. A Form 483 can carry many lines, so the rate counts citations and does not show what share of inspections drew one. Fiscal 2020 to 2021 inspection counts were low.

0510152012.2
FY18FY19FY20FY21FY22FY23FY24FY25

Source 22

Show the numbers
Fiscal yearCitations per 100 Form 483s
FY189.9
FY199.4
FY2010.9
FY2114
FY2212
FY2312
FY2410.7
FY2512.2
Computer controls rank sixth among FDA's drug citations in fiscal 2025

Most cited single lines on drug Form 483s. 316 lines in all.

Quality unit procedures not in writing or followed, 211.22(d)243
Investigations of discrepancies, 211.192164
No written production procedures, 211.100(a)162
Laboratory controls, 211.160(b)121
Cleaning and maintenance, 211.67(a)95
Computer controls, 211.68(b)87
Equipment design and location, 211.6381

Source 22

Show the numbers
CitationTimes cited
Quality unit procedures not in writing or followed, 211.22(d)243
Investigations of discrepancies, 211.192164
No written production procedures, 211.100(a)162
Laboratory controls, 211.160(b)121
Cleaning and maintenance, 211.67(a)95
Computer controls, 211.68(b)87
Equipment design and location, 211.6381

Six recent FDA warning letters, and what a periodic review would have read

LetterWhat FDA saysThe periodic review item
Ava Inc., April 14, 2026"A common username and password" on HPLC (liquid chromatography) equipment, analysts with administrator privileges, deleted GC (gas chromatography) sequences in the recycle bin. The firm's response says a software update let users bypass access restrictions.23Access, shared accounts, and changes including automatic updates
Fareva Amboise, April 10, 2026Operators could change particle counter dates and alarm limits. A vendor's calibration "deleted all electronic data", and "You did not have backups of this data."24Access, backup, supplier activity. Instruments count as systems
GC America, May 14, 2026Meter data deleted when a laptop shuts down, no audit trails or procedure produced, and a commitment to remove shared passwords. Annual product reviews were also missing since 2018.25Whether standalone instruments are in scope at all
Laboratorios Jaloma, May 22, 2026GC control software not validated, audit trails not enabled, inaccurate file dates, no backup.26Validation status, configuration, backup
Wisconsin Pharmacal, August 22, 2025Administrative privileges not controlled. The firm "does not review audit trails and raw analytical data".19Whether audit-trail reviews exist and were done
NWL Netherlands Services, April 1, 2025No unique usernames and passwords, laboratory staff with administrator rights, backups not adequately maintained.27Access and backup

FDA's own data integrity guidance explains why a shared login matters: "a unique individual cannot be identified through the login", and only shared accounts that are read-only are acceptable for viewing.28 A warning letter tells you what went badly wrong at one firm. It does not tell you how common a problem is, so read these as examples.

FDA's full-text warning letter search, tried on November 3, 2026, found no letter using "access review", and none pairing "periodic review" with "computerized". The 13 letters it returned for "periodic review" alone concern other things, such as ethics board review, suppliers and quality unit oversight. A search index proves little, so treat this as what we found. In these letters FDA writes about the control and leaves the name of the check to you.

10 · How reviews go wrong

Why a periodic review misses the finding: six habits and what UK inspectors have recorded

In shortThe common failure is a review that turns into a form: counts copied from reports, no check against the procedure, last year's actions assumed closed and an owner approving a review of their own year. UK inspection data put computerized systems among the ten most cited GMP deficiency groups in 2016, and Annex 11 ninth of the EU GMP chapters and annexes in 2019, the newest year listed by the UK regulator, the MHRA.

The habitWhat it looks likeWhy it happensWhat catches it
Counting in place of checking"37 changes, all closed"A count is quick. Reading each ticket's fields is slow.Check approval, test and verification on each GxP change, or on a stated sample
Reading tool by toolEach section passes, and the overlap goes unseenThe template has one section per toolPut the whole year on one timeline
Assuming last year's actions closed"Actions tracked in the quality system"Nobody re-opens the old reviewReport each action as closed on time, closed late or open. An open one is a finding
Losing the cumulative viewMany small changes, each approved, with no test of the wholeChange control looks at one change at a timeAsk PIC/S's question on "any cumulative effect of changes"3
A reviewer too close to the systemThe owner reviews their own yearThe owner has the knowledge and the accessMcDowall writes that people directly involved with a system have "a vested interest", and calls independence "of prime importance".29 Use a separate reviewer
Sampling that missesSix change requests read, none of the bad onesTime runs out, and McDowall calls reviews sampling exercises that can miss noncompliance29State the sample and why, and read all emergency changes
Computerized systems drew 9 critical deficiencies in MHRA's 2016 GMP data

Critical findings in the UK regulator's ten most cited deficiency groups, 2016. That group also drew 44 major and 120 other findings. It ranked fifth in 2015 and seventh in 2016.

Quality system38
Sterility assurance34
Production20
Complaints and recall11
Qualification and validation10
Premises and equipment9
Computerized systems9
Personnel8
Documentation2
Quality control2

Source 30

Show the numbers
GroupCritical findings
Quality system38
Sterility assurance34
Production20
Complaints and recall11
Qualification and validation10
Premises and equipment9
Computerized systems9
Personnel8
Documentation2
Quality control2

The same MHRA slides give examples a reviewer can use as a checklist. Data was lost from an autoclave control system after a software update because the backup ran only every three months. Users "had more authorisation on the chromatography data system than was permitted according to the SOP". A lock screen used a shared password, and one user could act under another's login.30

MHRA's newest data on its statistics page, last updated October 15, 2020, is a 2019 spreadsheet with no group totals. By our count of it, Annex 11 drew 240 of the 5,292 references cited across 258 inspections: 8 critical, 79 major and 153 other, ninth of the chapters and annexes. Clause 11, periodic evaluation itself, drew 12.31

Access controls dominate what FDA cites under 21 CFR 211.68 in fiscal 2025

All seven 211.68 lines on drug Form 483s, fiscal 2025. 153 citations in all, by our sum.

Controls over computers and record changes87
Written program of checks not followed38
Input and output not checked10
Backup not assured as exact and complete8
Records of checks not kept5
Backup file not maintained3
Program and validation record not kept2

Source 22

Show the numbers
FDA's lineTimes cited
Controls over computers and record changes87
Written program of checks not followed38
Input and output not checked10
Backup not assured as exact and complete8
Records of checks not kept5
Backup file not maintained3
Program and validation record not kept2
11 · What a weak review risks

What a late or thin system review puts at risk: results, batches, inspections and deals

In shortA missed review is a finding in its own right. The larger exposure is what it failed to catch: results nobody can attribute to a person, records that cannot be restored, and an inspection that turns one account into a question about every result. In one court case data integrity problems changed the outcome of a merger.

About $900 million

a Delaware court's "rough estimate" of the valuation hit from data integrity issues at a generic drug maker, in a merger dispute. It is wider than remediation cost alone.32

Akorn v. Fresenius, 2018
21%

of the company's implied equity value of $4.3 billion, which the court weighed in finding a material adverse effect.32

Same opinion
87

computer control citations on drug Form 483s in fiscal 2025, by our count of FDA's file.22

FDA data
Shared accounts and untested restores carry the heaviest consequence

How we would weigh common periodic review findings. Positions are a judgment, drawn from the letters and guidance in this guide. Your risk assessment decides.

How much it can put results in doubt →
Rare, heavy
Common, heavy
Rare, light
Common, light
Shared accountRestore never testedUnverified changeDeparted user activeLate access reviewMissed log reviewStale document
How often reviews find it →

Our reading of the sources 28,23,24,4

Show the numbers
ItemHow often reviews find it (0–1)How much it can put results in doubt (0–1)
Shared account0.360.80
Restore never tested0.160.66
Unverified change0.720.56
Departed user active0.820.33
Late access review0.860.18
Missed log review0.120.25
Stale document0.840.06

What each kind of gap can cost when it surfaces in an inspection

ExposureHow it plays out
Reported results in doubtIf anyone with a shared login could change data, you may have to show that past results were not affected. FDA's letters ask for a retrospective data integrity assessment and "interviews of current and former employees".23
Lost recordsA failed restore or a vendor visit that wipes data leaves nothing to show. One FDA warning letter describes a vendor's calibration deleting a site's data, with no backup.24
Wider inspection scopePIC/S tells inspectors to verify that reviews happened, "particularly with respect to any potential vulnerabilities regarding data integrity".3 An inspector who finds one weak system may sample more.
Outside helpRecent letters strongly recommend a qualified consultant.27,25 That cost lands on top of your own time.
Deals and partnersBuyers and partners read these records in due diligence, as Akorn shows.32

We found no public figure for what a single periodic review finding, or a late review, costs. Part C shows how to measure your own version.

12 · Cloud, suppliers, Windows 10

Windows 10's end of support, cloud releases and supplier visits: changes your change log may never show

In shortThe system a validated application runs on keeps moving, and some of that movement never reaches your change tickets. Windows 10 reached end of support on October 14, 2025. Any review period that crosses that date should say what happened to the laboratory PCs on it.

The changes least likely to appear in your own tickets need a separate question

Where a reviewer typically finds each kind of change. Illustrative; check your own systems.

UnlikelySometimesUsually
Your change ticketsSupplier release notesConfiguration auditInfrastructure recordsApplication upgradeUsuallyUsuallySometimesUnlikelyConfiguration setting changedSometimesUnlikelyUsuallyUnlikelyOperating system patchSometimesUnlikelySometimesUsuallyInstrument driver hotfixUsuallySometimesSometimesUnlikelyCloud supplier's monthly releaseSometimesUsuallyUnlikelyUnlikelySupplier's service visit or calibrationSometimesUnlikelyUnlikelyUnlikely

Illustrative · replace with your own numbers

Show the numbers
Your change ticketsSupplier release notesConfiguration auditInfrastructure records
Application upgradeUsuallyUsuallySometimesUnlikely
Configuration setting changedSometimesUnlikelyUsuallyUnlikely
Operating system patchSometimesUnlikelySometimesUsually
Instrument driver hotfixUsuallySometimesSometimesUnlikely
Cloud supplier's monthly releaseSometimesUsuallyUnlikelyUnlikely
Supplier's service visit or calibrationSometimesUnlikelyUnlikelyUnlikely
The moving partWhat the record saysThe question for the review
Operating systemsWindows 10 "will reach end of support on October 14, 2025" (long-term servicing releases follow their own dates).33 PIC/S expects migration planned "before the platforms reach an unsupported state", and unsupported systems isolated as much as possible.3 Microsoft sells Extended Security Updates for commercial editions through October 10, 2028, which it calls a "last resort" and a "temporary bridge".34Which PCs on this system ran an unsupported system this period, were they on paid updates, and what is the plan?
Automatic updatesOne firm told FDA a software update let users bypass access restrictions, and that it had disabled automatic updates.23What updates itself on this system, and who checks the effect?
Supplier visitsA vendor's calibration deleted a site's electronic data.24Which service visits happened this period, and were data backed up first?
Hosted systemsEMA's clinical guideline says its review items apply "whether the system is hosted by the responsible party or by a service provider", and lists updates of agreements with the provider.9Is the supplier assessment current, and did the provider's releases follow the agreed process?
Other systemsThe draft of Annex 11 asks about the combined effect of changes "in this, and in other systems".4What changed upstream or downstream that this system depends on?
13 · AI in the review

Can AI draft a periodic review? What FDA, EMA and draft Annex 22 say as of November 2026

In shortNo regulator has written a rule about AI drafting a system review. FDA has told one firm it must review AI-generated documents. FDA's draft guidance on AI sets aside internal workflows that do not affect quality or study reliability. Draft EU Annex 22 says generative AI should stay out of critical GMP applications, and asks that qualified people answer for outputs elsewhere. So AI can help with reading and drafting if a person decides and signs, and your quality unit should classify the use in writing.

TextWhat it says that bears on this workStatus, November 2026
Draft EU GMP Annex 22Applies to AI in critical applications "with direct impact on patient safety, product quality or data integrity". It does not apply to generative AI and large language models, "and such models should not be used in critical GMP applications". In non-critical uses, qualified people are responsible for checking outputs: a "human-in-the-loop".35Draft. EudraLex lists no Annex 22.13 EMA's report on its June 30, 2026 workshop says comments supported allowing such models and that the drafting group has discussed widening scope, with no revised text published.36
FDA draft guidance on AICovers AI producing data for regulatory decisions. It "does not address" AI used for "operational efficiencies (e.g., internal workflows, resource allocation, drafting/writing a regulatory submission) that do not impact patient safety, drug quality, or the reliability of results".37Draft of January 2025, still "not for implementation" on FDA's page. We found no final version.
FDA warning letter to one firmA firm used AI to create specifications, procedures and master records. "If you use AI as an aid in document creation, you must review the AI generated documents to ensure they were accurate and actually compliant with CGMP", citing 21 CFR 211.22(c).38 The letter went to one firm with other findings, so read it as an example. It sets no general policy.Letter 320-26-58, April 2, 2026
EMA AI reflection paperEMA's AI page lists the reflection paper and the guiding principles of good AI practice agreed with FDA.39Adopted September 2024; principles January 14, 2026
ISPE GAMP AI guideIndustry guidance on developing and using AI-enabled computerized systems in GxP areas.40July 2025
EU AI ActThe EU's risk-based law on AI. A later regulation, the AI Omnibus, delayed its high-risk dates.41 In our reading, a tool for internal compliance review is unlikely to be the law's main concern. Your legal team should confirm it.Omnibus in force July 27, 2026
ALCOA+Data should be attributable, legible, contemporaneous, original and accurate, plus complete, consistent, enduring and available.42 An AI-written draft must leave clear who decided what.MHRA, March 2018
Reading and drafting suit software, while severity and the conclusion stay with people

How we would split the work. A judgment, drawn from draft Annex 22's human-in-the-loop principle and 21 CFR 11.50.

Judgment it needs →
People decide
People, with help
Leave it
Software first
Sign the reviewChoose the conclusionRate severityWrite the sectionsCheck each changePull the exports
Hours it takes today →

Our reading of the sources 35,43

Show the numbers
ItemHours it takes today (0–1)Judgment it needs (0–1)
Sign the review0.120.82
Choose the conclusion0.120.68
Rate severity0.300.56
Write the sections0.760.30
Check each change0.800.18
Pull the exports0.840.07
The limits of automation here. Software can only read what a system exports. It cannot tell you who used a shared account, because no record says so. A citation shows where a sentence came from. It does not show that the conclusion is right. A tool that holds signed GxP records is also a computerized system: it goes on your inventory, you validate it for your use, and it gets its own periodic review. Nobody can buy a "validated" or "compliant" product, whatever a brochure says.
14 · How teams do it today

How IT Quality and CSV teams run a periodic review today, from the first export to the owner's signature

In shortAn IT Quality or CSV lead chases exports from several groups, writes the review section by section and takes it to the system owner. One published account puts a review at one to three days. Validation software helps schedule and store reviews, and we found no published evidence of how far it cuts the collecting.

Who touches a system's periodic review, and what each one cares about

IQ

IT Quality or CSV lead

Runs the schedule, gathers the evidence, writes the review and signs as reviewer.

Cares about: collecting less and thinking more.
SO

System owner

Runs the system for its users, owns its actions and approves the review.

Cares about: what the year shows, in plain words.
DI

Data integrity lead

Performs or oversees audit-trail reviews, and owns their procedure.

Cares about: one missed month turning into questions about all twelve.
IA

Identity and access analyst

Runs access certifications and the process for people who leave.

Cares about: the HR feed, so that removal does not depend on a ticket.
IT

IT operations and infrastructure

Own change tickets, incidents, backup jobs and restore tests.

Cares about: not being asked for the same export five times a year.
QH

Head of quality

Approves the criteria and any re-assessment.

Cares about: who owns each gap, and whether the program is on time.
Six steps for one review, and most of the waiting sits in step two

A typical path. Timings are illustrative. One published account puts the review itself at one to three days.

  1. 1Schedule

    The due date comes up on a tracker.

    IT Quality lead3 weeks ahead
  2. 2Request exports

    Six requests to six groups, and reminders.

    IT Quality lead, tool owners1 to 2 weeks
  3. 3Read and check

    Each record against the SOP.

    IT Quality lead1 to 2 days
  4. 4Write

    Ten or so sections with references.

    IT Quality lead1 day
  5. 5Decide

    Findings, severity, owners, conclusion.

    Reviewer, ownerAn hour or two
  6. 6Sign and track

    Signatures, then CAPAs in the quality system.

    Reviewer, owner, QADays

Illustrative · replace with your own numbers

Show the numbers
StepWhat happensWhoTime
ScheduleThe due date comes up on a tracker.IT Quality lead3 weeks ahead
Request exportsSix requests to six groups, and reminders.IT Quality lead, tool owners1 to 2 weeks
Read and checkEach record against the SOP.IT Quality lead1 to 2 days
WriteTen or so sections with references.IT Quality lead1 day
DecideFindings, severity, owners, conclusion.Reviewer, ownerAn hour or two
Sign and trackSignatures, then CAPAs in the quality system.Reviewer, owner, QADays

McDowall describes the classic form: read the validation plan and summary, hold an opening meeting, combine document review with laboratory observation and interviews, then close with findings classed on a four-point scale and a corrective action plan.20 He puts a review at "between 1–3 days", depending on size.29 That is from 2011, and we found nothing newer that publishes a figure.

Collecting and writing take about 22 of the 25 hours in one estimate

One estimate of a high-effort review by hand, about 25 hours in all. No published study breaks this down. Replace it with your own timing.

Changes and incidentsDeviations, CAPAs, past actionsAccess, backup, audit-trail registerWriting with referencesDeciding and signing
One review by hand5 h3 h7 h7 h3 h

Illustrative · replace with your own numbers

Show the numbers
Changes and incidentsDeviations, CAPAs, past actionsAccess, backup, audit-trail registerWriting with referencesDeciding and signing
One review by hand5 h3 h7 h7 h3 h

In-house templates, outside consultants, lifecycle software and automated drafting: four ways to run the reviews

WayHow it worksGood atWeak at
In house, with a templateSOP, Word template, tracker, exports by emailKnows the system. Low cash costLate at peak, varies by author, heavy on senior time
Outside consultantsA firm performs or supports reviews as a serviceIndependence and capacityCost per review, and learning your systems again each time
Validation lifecycle softwareA digital tool schedules reviews and holds templates and signaturesTracking and consistent recordsAsk how far it reaches into the evidence, beyond templates
Automated gathering and draftingSoftware reads the tools, lays out the year and drafts with citations. A person decidesCollecting and the cross-tool checksNeeds its own validation, and only sees what tools export

Validation teams are moving to digital tools. A vendor's 2025 survey of more than 300 professionals reported 58% using a digital validation system, up from 30% the year before.44 Its 2026 edition, with 614 respondents, reported 39% using or evaluating AI for validation.45 Both come from a vendor with an interest in the answer, so read them as direction. We found no public figure for how many reviews run late, or how many GxP systems a typical company holds. Section 18 shows how to count yours.

Part B · See it working

Botminds Computerized System Periodic Review, on one chromatography system's fictional year

Part A described the work without naming a product. This part shows how Botminds does it for a laboratory system due its review, starting from the example at the top of the page. Every company, person, system, record number and result on the screens is sample data. The conclusion you will read is a sample customer's conclusion about its own system: the product supports a validated state and is never itself validated, compliant or certified.

15 · One review, start to finish

One chromatography system's periodic review, from opening on September 24 to signature on October 7

In shortOmar Haddad, the IT Quality lead at Cobbleford Pharma, has a high-risk laboratory system due on October 15. One click reads six tools into a year calendar: 31 events placed, 4 gaps and 4 findings. He opens a drafted ten-section review, checks a citation against its record, decides each finding, chooses the conclusion and signs. Dr. Maya Chen, the system owner, approves next.

The review opens 21 days before it is due, and the next one is set when it closes
  1. Sep 24, 2026Review opened

    Scheduler sets the period and links last year's review.

  2. Oct 7, 2026Year read, decided, signed

    Omar signs as reviewer.

  3. Oct 15, 2026Due date

    Approval by Dr. Chen, the system owner, falls due.

  4. Oct 31 to Dec 15Four actions fall due

    Owners and dates in the quality system.

Fictional example from this guide

Show the numbers
WhenWhat
Sep 24, 2026Review opened
Oct 7, 2026Year read, decided, signed
Oct 15, 2026Due date
Oct 31 to Dec 15Four actions fall due
Oct 15, 2027Next review
1

The system's year, before anything is read

ChromaVault CDS at Plant 3 acquires and processes liquid and gas chromatography (HPLC and GC) data for release and stability testing. It is high risk and reviewed every 12 months, and this review's number is PR-2026-031. Its period runs from October 1, 2025 to September 30, 2026.

The screen is a calendar: twelve month columns and seven rows of evidence. Dashed rings already mark what the procedures expect, four quarterly access reviews and two restore tests. On the right are the six sources, each marked read-only.

The year, unread. The rings are the procedures' expectations, placed before any record is read.
2

"Load the year" reads six tools, one at a time

Each row fills as its tool is read: 37 changes, 14 incidents and 2 problems, 3 deviations and 2 CAPAs, 4 certifications covering 86 accounts, 363 of 365 backups and 2 restore tests, 11 of 12 monthly audit-trail reviews, and the last review's 2 actions.

Then the year is checked against the procedures. Hatched bands draw over the gaps, and a finding drafts beside each one. Green marks are as expected, amber an observation and red a finding. Clicking any mark opens its record.

The year, read. 31 events placed, 4 gaps against the procedures and 10 sections ready for review.
3

The worst gap: 16 weeks without an access review

After the certification on April 9, the next was due July 8 and done July 31, 23 days late. Inside that gap, two analysts who left on June 20 kept active accounts for 41 days, with no logins after they left. Removal depends on a manual ticket because the HR departures feed is not connected.

Clicking the band highlights its finding. It already names the fix: CAPA-2026-077, due November 30, with an interim check of departures against accounts every two weeks until it closes.

One gap and its finding. Severity, cited reasons and a proposed action with its owner and date. Everything here is a proposal.
4

Three more gaps, each with its finding

Emergency change CHG0048211, a driver hotfix on all 46 instruments, was closed June 19 with "post-implementation verification: to be attached", and nothing was attached. The August emergency patch, verified the next day, shows how it should look.

Last year's action A-2, to retire the shared administrator account cv_admin, was due March 31 and is still open. Three people used it this year, last on September 29. And August's audit-trail review was missed in a plant shutdown, caught up September 12, and the procedure has no rule for shutdowns.

Three more findings. An open action from the last review is always raised as a finding. The severity ratings are the sample site's.
5

The drafted review opens on the year and section 1

The review has ten sections: system and intended use, previous review actions, changes, incidents and problems, deviations and CAPAs, access, backup and restore, audit-trail review, documents, training and supplier, and the conclusion.

Each section carries its numbers, a cited draft and its criteria results. Across the review that is 35 citations to 26 records. The right side lists every source, grouped by where it was read from.

The drafted review. Sections, the year in one view, the first section's draft and criteria, and the source records.
6

A citation opens the record it came from

Omar clicks the citation behind "23 days late". The Q2 access certification opens beside the draft with the passage marked: due July 8, completed July 31, 86 accounts certified, 2 revoked as departed users, 9 privileged accounts reviewed and kept, and cv_admin kept as "pending retirement".

A note under the record gives the read date and says the original is unchanged. Nothing is written back to the source tools.

The record behind a citation. The passage that supports the sentence is highlighted in the original.
7

Omar decides every finding

Each finding offers three choices: raise an action, accept with a rationale that goes into the review and the audit trail, or mark it as not a finding. Omar raises the access finding, F-2, to Sam Patel with the interim check. He then raises the emergency change finding, F-1, to Dr. Chen by November 6. The shared account finding, F-3, goes to Sam Patel by October 31 with escalation to the site quality head. The audit-trail procedure finding, F-4, a revision of SOP-QC-0311 section 6.4, goes to Priya Ranvelle by December 15.

A finding decided. The decision, the person and the time go on the activity record.
8

The conclusion is proposed, and Omar chooses it

The proposal reads: the system remains in a validated state and fit for its intended use, with four actions. None changed a reported result, since no data was lost in the disconnects, the reprocessing deviation's CAPA was checked effective and release 2026.1 was validated. Keep the yearly frequency, because the high finding already has a CAPA and an interim check.

The screen offers three options and marks one as recommended. Omar chooses. The next review date, October 15, 2027, follows from the frequency.

Conclusion and next review. The conclusion is the sample company's own decision about its own system.
9

Two signatures, each with its meaning

Omar signs as IT Quality reviewer with the meaning "Reviewed: I reviewed the evidence and agree the conclusion". 21 CFR 11.50 asks a signed electronic record to show the signer's name, the date and time, and the meaning, and 11.70 asks that the signature be linked to its record.43 The review then goes to Dr. Chen to sign "Approved", and the four actions go to the quality system as CAPA tasks.

Sign as reviewer. Meaning, name and password, bound to this version of the record. Sample data.
Of 31 events placed on the year, four needed a decision, and one was rated high
Events placed on the year31
Gaps against the procedures4
Rated high1

Fictional example from this guide

Show the numbers
StageCount
Events placed on the year31
Gaps against the procedures4
Rated high1

What a careful IT Quality lead would still ask. The sample rates the shared administrator account Medium and says no finding changed a reported result. FDA says a shared login does not meet current good manufacturing practice (CGMP) for actions, because no one person can be identified, and the draft of Annex 11 calls such accounts a violation of data integrity.28,4 Three people used this account, so "no reported result changed" needs its own evidence, and your scale may well rate it higher.

Dr. Chen also completed the late Q2 certification and now approves the review that reports it. McDowall writes that people directly involved with a system have "a vested interest".29 The approver is a setting, and the site quality head is the other option. Both are judgment calls, and the product leaves them with the people who sign.

16 · Every other screen

The change, audit-trail and backup sections, the report, and the schedule across 64 systems

In shortBehind the case sit the other sections of the review with their own records, the report and action list, and the screens a program lead uses: the cycle's reviews, the schedule by risk tier, the system inventory, the dashboard and the rules.

How the review reads an emergency change and an audit-trail register

Two of the 37 changes were emergencies, and one of those left a finding
Standard: 31Normal: 4Emergency: 2
37changes
  • Standard31
  • Normal4
  • Emergency2

Fictional example from this guide

Show the numbers
TypeCount
Standard31
Normal4
Emergency2
The changes section. 37 changes, 36 verified after going live, and the finding with its proposed action.
The emergency change record. The closing note, marked in the original: verification "to be attached".
Last year's actions. Two actions, one closed, one open. The open one is always a finding, and that rule cannot be turned off.
The audit-trail section. The checker reads whether each review was done and followed up. It does not perform the audit-trail review.
Backup and restore. 363 of 365 backups, and a September restore test that failed on a faulty tape and passed on retest a week later, raised as an observation.

The report, the action list and the activity record from ChromaVault's review

The review report. Section by section, with criteria results and citations, after the reviewer's signature.
Actions from the review. Four raised as CAPA tasks, and last year's overdue action shown as carried to F-3.
The activity record. Every software step and every person's decision, in order, and it cannot be edited.

Reviews, schedule and inventory across Cobbleford Pharma's 64 GxP systems

Reviews in this cycle. 40 reviews, filterable by stage, risk tier and site, with due clocks.
The schedule by risk tier. Every system's next review by month, with an overdue column.
The GxP inventory. 64 systems, 22 high, 26 medium and 16 low, synced from the configuration database.

The dashboard and rules a head of quality approves

The program dashboard. On-time completion, hours per review by tier with by-hand estimates, findings by area and site, and conclusions. Sample data.
Your rules. The 12, 24 and 36 months are this sample company's settings. Each change saves as a new version, approved by the head of quality.
A second system's year. The same calendar on a global LIMS: 22 events, 2 gaps and 2 findings.
17 · Who reads, who signs

Six agents read and draft; an IT Quality reviewer and the system owner decide and sign

In shortA scheduler opens each review on time. Four read-only readers check one kind of evidence each. A writer drafts with a citation for every statement. The agents propose and people decide: a reviewer rules on each finding and signs, the system owner approves, and a re-assessment also needs the head of quality.

AgentIts jobWhat it never does
Review schedulerReads the inventory, applies your frequency, opens each review 21 days ahead and links the last reviewChanges a risk tier: it only proposes
Change and incident readerChecks each GxP change for impact assessment, approval, testing and verification, and links incidents to problems and fixesWrites to the service desk, or counts without citing
Quality record readerFinds deviations and CAPAs naming the system, and reports each past action as closed on time, closed late or openCloses or edits a quality record
Access and backup checkerReads certifications and account lists, compares the HR departures list with accounts, and reads backup reports and restore testsSees passwords, or personal data beyond name and role
Audit-trail review checkerChecks that each required review was done, on time and followed upPerforms the audit-trail review itself
Review writerDrafts the ten sections with a citation for every statement, and proposes findings, a conclusion and a next date. This step uses a generative model, as draft Annex 22 would class it.35Decides, signs or changes the stage

The sign-offs on a periodic review, and the rules that cannot be turned off

PersonDecides or signsThe meaning on the record
IT Quality reviewerEach finding, the conclusion and the frequency"Reviewed: I reviewed the evidence and agree the conclusion"
System owner, or site quality headApproval, as your setting says"Approved"
Head of qualityRe-assessment conclusions, and any change to frequencies or criteriaA third signature, and a new version of the rules

Four-eyes applies throughout: the reviewer and the approver are two different people. A signed review is locked, and a correction makes a new version. Roles, an audit trail on every step, and export of the signed record support an inspection. These are controls that support your compliance. Your validation for your intended use is still yours to perform, and the tool goes on your inventory.

From six read-only sources to a signed, cited review and its actions

Read, never changed

  • IT service management: changes, incidents, problems, configuration items
  • Quality system: deviations, CAPAs, prior actions
  • Identity governance: certifications, account lists, HR departures list
  • Backup reports: daily jobs, restore tests
  • Audit-trail review register and signed forms
  • Validation archive: past reviews, summaries, SOPs

From your team

  • Your frequency by tier and your criteria
  • Your reviewers and approvers
Agents read, check and draft Every statement opens the record behind it, with the read date
People decide every finding
Agents change no source record

What comes out

  • A ten-section review report with citations, as Word or PDF
  • A year calendar for the system
  • Open actions as CAPA tasks with owner and date
  • Next review date and frequency, written to the inventory on approval
  • The signed record and its full activity trail
All sources for the review. 26 records, grouped by where each was read from.

The design targets for a review program, and what they rest on

8.1 h

median per review, gathered and drafted, against about 25 hours by hand. The by-hand figure is an estimate.

Design target
21 days

ahead of each due date, every review opened and its evidence gathered.

Design target
91%

of reviews signed on time in a quarter, up from about 60% in the sample's baseline, an example figure.

Design target

These are the solution's design targets, to be measured in the live solution on your own systems. None is a result from a customer. Section 22 shows how to test them.

Part C · Are you ready to automate?

Automating periodic review of validated systems: what late reviews cost you, what the work returns and how to test it

You run IT Quality, computer system validation or site quality, or you answer for what a review says when an inspector opens it. This part is written for you: what thin and late reviews cost, what automating the gathering could return, whether your program is ready, and what to ask any vendor, including us.

18 · What it costs you

What collecting a system's year by hand costs your IT Quality team

In shortTwo costs sit apart. Senior hours spent collecting are certain, and you can time them this week. A finding that a review should have caught is rare and heavy, and you cannot predict it. We found no published cost for a periodic review, so the numbers that matter are the ones you measure.

1–3 days

for one review, in the one published practitioner account we found.29

McDowall, 2011
12 per 100

computer control citations per 100 drug Form 483s in fiscal 2025, by our arithmetic on FDA's file.22

FDA data
19 pages

in the draft of Annex 11, against 5 pages today. It would add to what a review reads if adopted as written.4,1

Draft, not in force
Collecting is where the hours on one review can come down

Hours for one periodic review. By hand is an estimate. With the solution is a design target, measured in the live solution. Replace both with your own timing.

By hand (estimate)With the solution (design target)
Changes, incidents and problems5 hours0.5 hours
Deviations, CAPAs and last review's actions3 hours0.5 hours
Access, departures, backups and restores4 hours0.5 hours
Audit-trail review register3 hours0.5 hours
Writing sections with references7 hours3.5 hours
Deciding findings and signing3 hours2.6 hours

Illustrative · replace with your own numbers

Show the numbers
By hand (estimate)With the solution (design target)
Changes, incidents and problems5 hours0.5 hours
Deviations, CAPAs and last review's actions3 hours0.5 hours
Access, departures, backups and restores4 hours0.5 hours
Audit-trail review register3 hours0.5 hours
Writing sections with references7 hours3.5 hours
Deciding findings and signing3 hours2.6 hours
What we could not find published. We found no public figure for hours per review beyond the 2011 account above, for how many reviews run late, how many GxP systems a company holds, what a review finding costs or how accurate any AI tool is at this work. Vendors may quote their own. Ask how they were measured, and measure yours.

Timing one review and counting your inventory: your own baseline in a week

CostWhere it hidesHow to find your number in a week
Hours per reviewIT Quality, CSV and tool owners answering export requestsTime the next review end to end, including the people you ask
Reviews a yearAn inventory that disagrees with the trackerCount by tier, then apply high ÷ 1 + medium ÷ 2 + low ÷ 3, or your own cycles
Reviews signed lateExtensions granted by emailCompare signed date with due date for the last 12 months
Gaps a review did not raiseNowhere, until something surfacesPick one signed review. Check access, departures and emergency changes yourself, and count what it missed
Actions carried overPrior reviews nobody re-opensList last cycle's actions and mark each closed on time, closed late or open
Departure exposureBetween HR's list and each system's accountsCompare the HR list with accounts on your three highest-risk systems
Outside helpConsultant invoices under project budgetsPull last year's review and remediation invoices

The rushed review, the expert's hour and other periodic review costs a calculator misses

The review written in the last weekWhen collecting eats the time, the thinking gets what is left. A late start shows in the quality of the conclusion.
Your best people as couriersThe lead who knows the system best spends two days asking for exports, and that is an expensive way to move files.
The action that keeps coming backA shared account carried for another year is the same risk, for longer, with your signature on it twice.
Your answer in an inspectionPIC/S tells inspectors to verify that reviews happened.3 A review whose statements each open their record is quicker to answer for than a folder of exports.
Sampling you could not affordMcDowall calls reviews sampling exercises.29 When reading every change costs little, a sample stops being a time limit and becomes a choice.
19 · Your return

What automating the gathering returns on your yearly review count

In shortMost of the return is senior hours moved from collecting to judging. A smaller part comes from reviews signed on time. Findings caught earlier are worth more, and you should not count them until you have measured them. Every default below is an assumption for you to replace.

Five places a review program gets time or risk back, each with its formula

Collecting

Evidence gathered before you open the review

Six tools read in place of six export requests and their reminders.

reviews a year × hours saved × hourly cost
Writing

A cited draft to correct

Sections start written, and each reference is already there.

reviews a year × writing hours saved × hourly cost
Timeliness

Reviews opened on a fixed lead time

Each review starts on the same lead time, so fewer signatures run late and fewer extensions need chasing.

reviews a year × late share avoided × hours per late review × hourly cost
Tool owners

Fewer requests to IT and identity teams

The same export stops being asked for many times a year.

requests avoided × minutes each × hourly cost
Findings

Gaps found by you, in an ordinary month

Hard to value. Count them, and leave them out of the sum.

gaps found that last year's method missed

Your hours back across a year of system reviews

Your program
Hours per review
Late reviews
Your cost
Illustrative yearly value
Review time today, valued$0
IT Quality hours freed0
Hours freed, valued$0
Late reviews avoided, valued$0
Yearly value, less your cost$0

Formulas: hours freed = reviews × (today − with automation). Late value = reviews × (late share today − with automation) ÷ 100 × extra hours × hourly cost. Yearly value = hours freed × hourly cost + late value − your cost. Findings are left out on purpose. These are planning figures, and no outcome is promised.

Hours freed scale directly with your review count, at the defaults above

Reviews a year × 16.9 hours freed per review. Assumptions, for you to replace.

20 reviews a year338 hours
40 reviews a year676 hours
60 reviews a year1,014 hours
100 reviews a year1,690 hours

Illustrative · replace with your own numbers

Show the numbers
Program sizeHours freed
20 reviews a year338 hours
40 reviews a year676 hours
60 reviews a year1,014 hours
100 reviews a year1,690 hours
20 · Readiness check

Is your periodic review program ready to automate? Eight questions on inventory, SOPs and signatures

In shortSoftware can only check what your procedures make checkable. Score each question from 0 to 2. Nothing you choose leaves this page.

1
A GxP inventory you trust

Do you hold a current inventory of GxP systems with a risk tier and an owner for each?

Why it mattersThe schedule is built from it, and a laptop-connected meter of the kind in GC America's letter is easy to leave off.25
A strong answer"One list, synced from the configuration database, every system tiered, every owner named."
2
Your baseline on one review

Have you timed a review end to end, including the people you ask for exports?

Why it mattersWithout it, any claimed saving is a guess, and you cannot judge a pilot.
A strong answer"Three reviews timed by tier, with on-time rate for the last 12 months."
3
A procedure software can check against

Does your SOP state scope, frequency by tier and pass criteria in terms a record can answer?

Why it matters"Access reviewed regularly" cannot be checked. "Within 14 days of due" can.
A strong answer"Numbered criteria with limits, and the draft Annex 11 list mapped to them."
4
Read-only access to the six sources

Can your service desk, quality system, identity tool and archives give read-only access or a scheduled export?

Why it mattersReading must change nothing, and manual exports bring the collecting back.
A strong answer"Read-only service accounts agreed with each owner, and a mailbox for the backup reports."
5
Who signs, and how independent they are

Is the reviewer separate from the person who runs the system, with a set rule for who approves?

Why it mattersA faster review by the wrong person is still a weak review.29
A strong answer"IT Quality reviews, the owner approves, and the site quality head approves where the owner's own task is a finding."
6
How you class AI drafting

Has your quality unit decided in writing how AI-drafted text in a GMP review fits draft Annex 22 and your procedures?

Why it mattersDraft Annex 22 treats critical and non-critical uses differently, and it is still a draft.35 An inspector will ask for your reasoning.
A strong answer"A signed risk assessment: draft only, read-only, every statement cited, a qualified person decides."
7
Where actions go

Do review actions enter your quality system as tracked CAPAs that the next review can read?

Why it mattersA finding that stays in a PDF is the one that comes back next year.
A strong answer"Each action has an owner and a date in the quality system, and open ones become findings automatically."
8
Validating the review tool itself

Are you ready to put the tool on your inventory, validate it for your use and review it in turn?

Why it mattersA tool holding signed GxP records is a computerized system. No vendor can do this part for you.
A strong answer"CSV lead assigned, risk assessment started, supplier assessment planned."
9
If every system's year were already laid out · for reflection

If you could see each system's year on one page, every month, what would you do with the time: review more often, read all the emergency changes, or fix the gaps that keep coming back? Not scored.

0–6

Explore

Clean up the inventory and write checkable criteria. Time one review by hand. These pay off with or without software.

7–11

Ready to pilot

Pick three systems across tiers, including one already reviewed, and run the parallel test in section 22.

12–16

Ready to implement

Plan by risk tier, starting with the systems due next, and validate the tool as part of the rollout.

21 · Questions for any vendor

What to ask any periodic review software vendor, on access, citations, signatures and AI (ask us too)

In shortAsk to see it on one of your own systems' years. A vendor who shows a template and a calendar is selling scheduling. A strong one finds a gap in your records and opens the record behind it.

AskA good answerA warning sign
Reading the year
Show me one of my systems' years, read from my tools.A live run on your exportsOnly the vendor's sample
Do you check each change's fields, or count tickets?Approval, test and verification, per record, with the field citedTotals by type
Does a gap between two tools show as one finding?Yes, as with a late access review and a departureOne section per tool
What happens to an open action from the last review?Always a finding, and the rule cannot be switched offA setting you can turn off
Citations and evidence
Open the record behind this sentence.The original, with the passage marked and the read dateA summary or a bare link
Can a statement exist without a citation?No"Most have one"
Does anything write to my source systems?Read-only, and you can test the accountsA broad service account
People, signatures and records
Who decides severity and the conclusion?A named person, on each finding, with the reason keptAuto-accepted drafts
How do signatures meet 21 CFR 11.50 and 11.70?Name, date and time, and meaning, linked to that version43A typed name on a PDF
What happens to a signed review?Locked. A correction makes a new version, and all of it is on the audit trailEditable after signing
Validation and AI
Is your product "validated" or "compliant"?"No product can be. Here is what supports your validation""Fully Part 11 compliant, out of the box"
Which steps use a language model, and how does that fit draft Annex 22?Named steps, draft only, people decide, status of the draft stated35,36"AI-validated" or no answer
How were your time and accuracy numbers measured?Method and sample shown, targets marked as targetsA bare percentage
What security and audit credentials do you hold?An independent report you can read. We hold SOC 2 Type II and manage information security to ISO 27001Claims of GxP certification, which does not exist
22 · Testing it on three systems

A 12-week parallel test on three validated systems, one already reviewed by hand

In shortTake three systems, one per risk tier. Include a system whose signed review you already have, so you can compare what each method found. Measure hours, gaps and citation accuracy, and decide against numbers you set beforehand.

Three systems in 12 weeks, with the go or no-go decision on your own numbers

An illustrative plan. Adjust to your systems and your validation procedure.

Your teamVendor
Pick systems, baseline hours and on-time rate
Risk assessment and AI classification
Read-only connections and your criteria
Parallel run: one system already reviewed
Parallel run: two systems due next
Score gaps, citations and hours
Decide, and plan validation for use
Week 036912

Illustrative · replace with your own numbers

Show the numbers
ActivityFromTo
Pick systems, baseline hours and on-time rate02
Risk assessment and AI classification03
Read-only connections and your criteria14
Parallel run: one system already reviewed36
Parallel run: two systems due next59
Score gaps, citations and hours810
Decide, and plan validation for use1012

The six measures that decide a periodic review pilot

MeasureHow to take itPass line (set your own)
Hours per reviewYour baseline against the pilot, including tool owners' timeAt least half gone
Gaps foundOn the system already reviewed: what the signed review found, what the pilot found, and which of those a person confirmsEvery gap from the signed review, plus any new ones confirmed
False findingsFindings a reviewer marks "not a finding"Few enough that reading them costs less than finding them
Citation accuracyOpen a sample of 50 citations and check that each says what the sentence saysEvery one correct, or the error explained and fixed
On-time rateSigned by due date, on the systems in the pilotAll of them
Reviewer's confidenceAsk the signer, before signing: would you defend this in an inspection?A plain yes, with reasons
Deep questions to settle before you scale

Old gaps. If the first run finds gaps in earlier periods, who assesses them, and how do they enter your deviation process? Agree this before you connect anything.

Sampling. If software can read every change, does your procedure still say "sample"? Decide what to read in full, and write down why.

Severity. Who sets the scale? The sample in Part B rates a shared administrator account Medium. FDA and the Annex 11 draft speak about shared accounts more strongly, so your scale may rate it higher.28,4

Independence. When the system owner carried out a task that became a finding, should that owner still approve? Name the alternative in your procedure.

The draft. When Annex 11 is finalized, who updates the criteria, and who approves that change? Plan for one version change in the first year.

Systems outside the list. Standalone instruments and spreadsheets often sit outside IT's tools. Decide how they get into scope, or write down why they stay out.

23 · FAQ

Computerized system periodic review: the questions people search for

In shortEach answer stands alone. Status statements are as of November 3, 2026.

What is a computerized system periodic review?

It is a scheduled, documented check that a validated GxP system is still in its validated state and fit for its intended use. The reviewer reads the period's changes, incidents, deviations, access reviews, backups, audit-trail reviews and last review's actions against the company's procedures. The review ends in a signed conclusion and tracked actions.

How often should a computerized system periodic review be done?

As often as you can justify by risk. EU GMP Annex 11 sets no interval, and the PIC/S data integrity guidance and the 2025 draft of Annex 11 ask for a frequency based on risk. One consultancy's published convention is yearly for high-impact systems and every two to three years for lower-risk ones, which is a company choice. OECD's GLP guidance adds one number: a user review at least yearly.

What does EU GMP Annex 11 say about periodic review?

Clause 11 says computerized systems "should be periodically evaluated to confirm that they remain in a valid state and are compliant with GMP". It lists functionality, deviations, incidents, problems, upgrade history, performance, reliability, security and validation status, "where appropriate". The Commission's page still listed this January 2011 text on November 3, 2026.

Has EU Annex 11 been revised?

Not as of November 3, 2026. A draft went out for consultation from July 7 to October 7, 2025, and its section 14 covers periodic reviews at length. EMA's inspectors' work plan targets Q4 2026 for giving the Commission a final text, which is a target with no adoption date. The 2011 version remains the one listed in EudraLex Volume 4.

Does FDA require a periodic review of computer systems?

FDA's drug rule does not use the term. 21 CFR 211.68 requires a written program of routine checks on computers, plus controls on access, input and output, and backup. Many companies meet this with a periodic review, and many also follow EU expectations. FDA cited the access line of 211.68(b) 87 times in fiscal 2025 on drug Form 483s, the lists of observations given at the close of an inspection.

What should a periodic review template or SOP include?

At a minimum: changes, incidents and problems, deviations and CAPAs, access reviews and departures, backup and restore tests, audit-trail reviews, documents and training, supplier status and last review's actions. The 2025 draft of Annex 11 adds the combined effect of changes, undocumented changes, regulatory changes and a final review at retirement. It should end with a conclusion, a next date and named actions.

What does GAMP 5 say about periodic review?

GAMP 5, second edition, is ISPE's industry guidance on risk-based GxP computerized systems, published in July 2022, and it carries no legal force. ISPE's published table of contents lists Appendix O8, Periodic Review. We did not read the paid text, so we cannot say what O8 asks about frequency, and you should read it yourself if your procedures rest on it.

What is the difference between periodic review and revalidation?

A periodic review reads records to decide whether a system is still in its validated state. Revalidation runs tests to prove that it works, after a change or because a review found a reason. A review can conclude that revalidation is needed, in whole or in part, and a recent major revalidation can justify postponing a review under OECD's guidance.

Who should perform a periodic review of a validated system?

Usually an IT Quality or CSV lead, with input from the system owner, process owner, IT and QA. Rules rarely name the performer. R.D. McDowall's 2011 practitioner account warns that people directly involved with a system have a vested interest and stresses independence, so many companies have IT Quality review and the owner approve.

Is an audit-trail review part of a periodic review?

They are separate checks that connect. An audit-trail review looks at log entries, often per batch or per month, and a periodic review checks whether those reviews were done on time and followed up. The periodic review does not repeat them. The draft of Annex 11 lists "conduct of, and actions from, audit trail reviews" in its scope.

Do cloud and SaaS systems need a periodic review?

Yes, if they are used for GxP work, and hosting does not move the duty. EMA's clinical guideline says its review items apply whether the system is hosted by you or a service provider. A review of a hosted system should also read the supplier's releases, the supplier assessment and the service agreement.

Can AI write a periodic review?

AI can gather records and draft text, while a qualified person must decide findings and sign. Draft EU Annex 22 says generative AI and large language models should not be used in critical GMP applications, and asks for a human in the loop elsewhere. It is still a draft, and EMA reports that the wording is under discussion, so your quality unit should class the use in writing.

Can a periodic review tool be validated or Part 11 compliant out of the box?

No. Validation is something you do for your intended use, and compliance belongs to your operation. A vendor can supply controls such as unique signatures with their meaning, locked records and audit trails, along with documents that support your validation. The tool also goes on your inventory and gets its own periodic review.

24 · One-page summary

Eight steps for one system's periodic review, where the rules stand, and 14 terms

Print this page

In shortEight steps from opening the review to setting the next date, where each rule stands as of November 3, 2026, the readiness bands, and the terms this guide uses.

The method
  1. Open the review with lead time, and set the period by the system's risk tier.
  2. Gather the period from all six sources, and last review's actions.
  3. Lay the year on one calendar with what your procedures expected.
  4. Do the subtraction: days late, days exposed, actions overdue.
  5. Ask the bigger questions: combined effect of changes, unsupported platforms, supplier changes.
  6. Write each finding with its evidence, a severity, an owner and a date.
  7. A separate reviewer decides, and an approver signs with a stated meaning.
  8. Send actions to the quality system, and set the next date by risk.

Readiness: score 0–2 on eight questions: 0–6 explore · 7–11 pilot · 12–16 implement.

As of November 3, 2026: Annex 11 at its January 2011 revision; revision and Annex 22 still drafts, Q4 2026 a target · PIC/S PI 041-1 from July 1, 2021 · OECD No. 17 from 2016 · ICH E6(R3) in the EU from July 23, 2025 · 21 CFR 211.68 in the 2025 CFR · FDA's AI guidance a draft · FDA CSA, device software only, February 3, 2026 · AI Omnibus in force July 27, 2026.

14 terms
GxP
Good practice rules: manufacturing (GMP), laboratory (GLP), clinical (GCP) and others.
Computerized system
Software, hardware and the people and procedures around them, doing regulated work.
Validation
Documented proof that a system does its intended job.
Validated state
The condition in which that proof, and its controls, still hold.
Periodic review
The scheduled, documented check of that state.
CSV
Computer system validation, the discipline and often the team.
System owner
The person answerable for running a system and its actions.
Access review
A manager confirming each account and role. Also called a certification.
Audit trail
A system's own time-stamped log of who did what.
CDS, LIMS, EDC
Chromatography data system, laboratory information management system, electronic data capture.
Form 483
FDA's list of observations, given at the close of an inspection.
CAPA
Corrective and preventive action, with a check that it worked.
GAMP 5
ISPE's industry guide to risk-based computerized systems; second edition, July 2022.
ALCOA+
Attributable, legible, contemporaneous, original, accurate; plus complete, consistent, enduring, available.
25 · Sources

Sources

Accessed November 2026. Regulatory status statements are as of November 3, 2026. Warning letters are cited from FDA's own copies, for what each letter says.

  1. European Commission, EudraLex Volume 4, EU GMP Annex 11: Computerised Systems, revision January 2011, in operation from June 30, 2011. health.ec.europa.eu
  2. European Medicines Agency, Good manufacturing practice questions and answers, EU GMP guide annexes, Annex 11, question 7, February 2011. ema.europa.eu
  3. PIC/S, PI 041-1, Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments, July 1, 2021, section 9.3. picscheme.org
  4. European Commission and PIC/S, draft EU GMP Annex 11: Computerised Systems, consultation July 7 to October 7, 2025, sections 11, 12, 14 and 16. picscheme.org
  5. OECD, Series on Principles of Good Laboratory Practice No. 17, Application of GLP Principles to Computerised Systems, ENV/JM/MONO(2016)13, 2016, paragraphs 89, 90 and 92, as hosted by BfR. bfr.bund.de
  6. 21 CFR 211.68, Automatic, mechanical, and electronic equipment, 2025 edition, the newest on govinfo on November 3, 2026. govinfo.gov
  7. ISPE, GAMP 5 Guide: A Risk-Based Approach to Compliant GxP Computerized Systems, Second Edition, July 2022, publisher's page and table of contents (Appendix O8, Periodic Review). The paid text was not read. ispe.org · table of contents
  8. 21 CFR 211.180(e), General requirements for records, 2025 edition. govinfo.gov
  9. European Medicines Agency, Guideline on computerised systems and electronic data in clinical trials, EMA/INS/GCP/112288/2023, March 9, 2023, section A2.9. ema.europa.eu
  10. FDA, Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers, guidance, October 2024, question 12. fda.gov
  11. ICH, E6(R3) Good Clinical Practice, Step 4, January 6, 2025, sections 4.3.4, 4.3.7 and 4.3.8. database.ich.org
  12. European Medicines Agency, 3-year work plan of the GMP/GDP Inspectors Working Group, January 2026 to December 2028: Annex 11 target date Q4 2026, to give the Commission a final text. ema.europa.eu
  13. European Commission, EudraLex Volume 4 page, read November 3, 2026: Annex 11 listed at "revision January 2011"; no Annex 22 listed. health.ec.europa.eu
  14. 21 CFR 11.10, Controls for closed systems, 2025 edition. govinfo.gov
  15. 21 CFR 11.100 and 11.300, electronic signature and password controls, 2025 edition. govinfo.gov
  16. FDA, Quality Management System Regulation page: took effect February 2, 2026, incorporating ISO 13485:2016. fda.gov
  17. FDA, Computer Software Assurance for Production and Quality Management System Software, guidance issued February 3, 2026, superseding the version of September 24, 2025. fda.gov
  18. ISPE, Microlearning: GAMP Basic Principles, Operational Phase for GxP Regulated Systems, course page. ispe.org
  19. FDA, Warning Letter 320-25-103, Wisconsin Pharmacal Company, LLC, August 22, 2025. fda.gov
  20. R.D. McDowall, "Periodic Reviews of Computerized Systems, Part II", Spectroscopy, November 1, 2011. spectroscopyonline.com
  21. G. Moreno and M. Montull, "CSV periodic reviews", QbD Group, July 23, 2025, a consultancy's article. info.qbdgroup.com
  22. FDA, Inspection Observations, Excel files for fiscal 2018 to fiscal 2025 (inspections ending by September 30, 2025), Drugs tab. Counts by row are FDA's; the sums, ranks and rates are our arithmetic. FDA notes that hand-prepared Form 483s are not in the files. fda.gov
  23. FDA, Warning Letter 320-26-64, Ava Inc., April 14, 2026. fda.gov
  24. FDA, Warning Letter CMS 723502, Fareva Amboise, April 10, 2026. fda.gov
  25. FDA, Warning Letter CMS 727602, GC America, Inc., May 14, 2026. fda.gov
  26. FDA, Warning Letter 320-26-78, Laboratorios Jaloma S.A. de C.V., May 22, 2026. fda.gov
  27. FDA, Warning Letter 320-25-59, NWL Netherlands Services B.V., April 1, 2025. fda.gov
  28. FDA, Data Integrity and Compliance With Drug CGMP: Questions and Answers, guidance, December 2018, question 5. fda.gov
  29. R.D. McDowall, "Periodic Reviews of Computerized Systems, Part I", Spectroscopy, September 1, 2011. spectroscopyonline.com
  30. MHRA, GMP Inspection Deficiency Data Trend 2016, slides 4, 5 and 81 to 83. The newest deck on MHRA's page with group totals and worked examples. assets.publishing.service.gov.uk
  31. MHRA, Good manufacturing practice inspection deficiencies, statistics page, last updated October 15, 2020, and its 2019 Deficiency Data spreadsheet. Counts by row are MHRA's; the tallies and the rank are our arithmetic. gov.uk
  32. Akorn, Inc. v. Fresenius Kabi AG, Delaware Court of Chancery, October 1, 2018; affirmed December 7, 2018. courts.delaware.gov
  33. Microsoft, Windows 10 Enterprise and Education lifecycle page: end of support October 14, 2025; long-term servicing releases follow their own dates. learn.microsoft.com
  34. Microsoft, Product Lifecycle FAQ, Extended Security Updates: Windows 10 Enterprise, Education and Pro in commercial use, ESU year 3 ends October 10, 2028. learn.microsoft.com
  35. European Commission and PIC/S, draft EU GMP Annex 22: Artificial Intelligence, consultation July 7 to October 7, 2025, section 1. picscheme.org
  36. European Medicines Agency, report of the multistakeholder workshop on artificial intelligence guidance development (Annex 22), June 30, 2026, EMA/156789/2026. ema.europa.eu
  37. FDA, draft guidance, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products, January 2025, Docket FDA-2024-D-4689. fda.gov
  38. FDA, Warning Letter 320-26-58, Purolea Cosmetics Lab, April 2, 2026. fda.gov
  39. European Medicines Agency, Artificial intelligence page: reflection paper adopted September 2024; FDA and EMA guiding principles of good AI practice, January 14, 2026. ema.europa.eu
  40. ISPE, GAMP Guide: Artificial Intelligence, July 2025, publisher's page. ispe.org
  41. European Commission, AI Act page, timeline after the AI Omnibus, Regulation (EU) 2026/1744, in force July 27, 2026. digital-strategy.ec.europa.eu
  42. MHRA, GXP Data Integrity Guidance and Definitions, March 2018, sections 3.10 and 6.17.2. assets.publishing.service.gov.uk
  43. 21 CFR 11.50, Signature manifestations, and 11.70, Signature/record linking, 2025 edition. govinfo.gov
  44. Kneat, State of Validation annual report, listing on Pharmaceutical Online, July 1, 2025; a vendor's survey of more than 300 professionals. pharmaceuticalonline.com
  45. D.J. Nagle, "2026 State of Validation Report", Pharmaceutical Engineering, July 1, 2026, sponsored content from Kneat, a validation software vendor. ispe.org
Next step

See it on one of your own validated systems.

Explore the solution, or bring one system and a year of its records, and we will lay out that year with you, every statement opening the record it rests on.

botminds.ai The complete guide to computerized system periodic review · November 2026. Cobbleford Pharma, Plant 3, ChromaVault CDS, every other system, person, record number and figure in the example and the screens are fictional. Regulatory status is as of November 2026; check the sources before relying on it. This guide is general information and is not legal advice. Software cannot itself be GxP compliant or certified: the review tool sits on your inventory, you validate it for your use, and it carries controls that support your compliance.